Key facts
- This page summarizes HighCape Partners GP II, LLC's Form 4 filing for AZIYO BIOLOGICS, INC. (ELUT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 28 Dec 2022, 14:55.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
This option vests in full and shall be fully exercisable on June 20, 2023, subject to Mr. Rakin's continuing in service on the Issuer's board of directors through the vesting date.
Footnote F2
Granted to Kevin L. Rakin as non-employee member of the Issuer's board of directors.
SEC remarks
Due to the limitations of the electronic filing system, each of HighCape Capital, L.P., HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Partners GP, LLC, HighCape Partners GP, L.P., HighCape Co-Investment Vehicle I, LLC, HighCape Co-Investment Vehicle II, LLC, HighCape Capital, LLC, W. Matthew Zuga and Kevin L. Rakin filed on a separate Form 4 dated December 27, 2022.